Kulkarni P, Lohidasan S, Mahadik K. Bioanalytical method development for momordicinin and its application to long-term pharmacokinetics in diabetic rats.
Drug Dev Ind Pharm 2021;
47:1064-1071. [PMID:
33818228 DOI:
10.1080/03639045.2021.1908337]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
OBJECTIVE
To develop and validate bioanalytical RP-HPLC method to evaluate pharmacokinetics and tissue distribution pattern of momordicinin (MRN).
SIGNIFICANCE
MRN is one of the major cucurbitane triterpenoid found in Momordica charantia Linn (MC). However, MRN has not been explored for its pharmacokinetic profile, tissue distribution, and stability in order to establish it as an antidiabetic agent.
METHODS
In 28 days pharmacokinetic study, 54 diabetic male wistar rats were divided into three different groups and administered with 25, 50, and 100 mg/kg MRN orally. The blood samples were collected at 1, 7, 14, 21, and 28th day of the treatment and plasma quantification of MRN was done by validated RP-HPLC method. The rats were sacrificed at end of the study for tissue distribution.
RESULTS
The developed method was successfully applied to investigate pharmacokinetic profile of MRN. In pharmacokinetic analysis, the Cmax for 25, 50, and 100 mg/kg was found to be 8.412, 10.443, and 11.829 µg/mL respectively suggesting the dose dependent activity. The maximum plasma concentration was achieved at 2 h for all doses. MRN showed major distribution in liver followed by kidney, spleen, and pancreas.
CONCLUSION
The newly developed and validated method was used to assay MRN in plasma as well as in tissues to evaluate pharmacokinetics of the drug for the first time. Undoubtedly, these findings can be taken into consideration while concluding its therapeutic effects after oral administration.
Collapse